Pharmaceutical company offering formulation capsules, mushroom extracts and recreational psilocybin Optimi Health Corp. (CSE: OPTI) (OTCMKTS: OPTHF) announced having entered into a psilocybin supply agreement with Halucenex Life Sciences Inc. which is a wholly owned subsidiary of Creso Pharma Ltd. (ASX: CPH).
Optimi confirmed thet the supply agreement concerns to the entirety of the recently harvested first batch of psilocybe cubensis mushrooms at the company’s Princeton, British Columbia facility. Optimi Health will be supplying the mushrooms to Halucenex in form of whole, dried mushroom fruiting bodies.
“This first supply agreement, coming so soon after our first complete cultivation cycle, is a powerful affirmation of our decision to pursue the development of natural, GMP psilocybin. From this initial proof-of-concept batch, our cultivation team will continue to scale our operations to meet the demands of the sector, domestically and internationally with licensed entities and for individual patients within Canada according to the terms of the Special Access Program,” said the CEO of Optimi Health, Bill Ciprick.
On the other side the chief executive of Halucenex, Bill Fleming, believes this agreement is one which will benefit the two companies.
“We’re very excited to be moving forward on this supply agreement with the team at Optimi Health. Among our top priorities in the development of a psychedelic-assisted psychotherapeutic model for conditions such as anxiety and post-traumatic stress disorder has been to secure a safe, consistent supply of GMP psilocybin,” added Fleming.
